Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
309 GBX | +3.00% | +6.55% | +9.19% |
04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
04-26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.19% | 3.2B | |
+31.13% | 699B | |
+25.07% | 571B | |
-4.27% | 364B | |
+18.35% | 326B | |
+3.31% | 286B | |
+14.38% | 236B | |
+4.60% | 198B | |
-12.60% | 194B | |
-4.53% | 154B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Hutchmed, AstraZeneca Dose First Patient in China Phase III Study of Combination Therapy for Lung Cancer